Upcoming event

Tags

3D reconstruction, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, biomarkers, Cabozantinib, Carcinoma, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, histology, imaging, IMDC risk model, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic disease, metastatic RCC, Mortality, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, papillary tumour, Partial nephrectomy, precision therapy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era

The LANCET Oncology, September 2026

Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma

The New England Journal of Medicine, July 2026

Management of lymph node–positive renal cell carcinoma: Updated recommendations from the European Association of Urology renal cell carcinoma guidelines panel

European Urology, May 2026

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group

World Journal of Urology, June 2026

Sutureless purely off-clamp robotic partial nephrectomy: Evidence from a randomized controlled noninferiority trial

European Urology, May 2026

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

THE LANCET Oncology, June 2026

Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma

ASCO2026

Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial

ASCO2026

ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial

ASCO2026

KIM-1 in advanced papillary and clear cell renal cell carcinoma

European Urology, April 2026

Development and internal validation of a novel prognostic score for real-world renal cell carcinoma patients eligible for adjuvant therapy

AUA26, May 2026

Association of serum Kidney Injury Molecule (KIM-1) with treatment response and survival in metastatic kidney cancer

AUA26, May 2026

Next